The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study
Open accessAbstract
Background Clinical phage therapy is often delivered alongside antibiotics. However, the phenomenon of phage-antibiotic synergy has been mostly studied in vitro. Here, we assessed the in vivo bactericidal effect of a phage-antibiotic combination on Acinetobacter baumannii AB900 using phage øFG02, which binds to capsular polysaccharides and leads to antimicrobial resensitisation in vitro . Methods We performed a two-stage preclinical study using a murine model of severe A. baumannii AB900 bacteraemia. In the first stage, with an endpoint of 11 h, mice ( n = 4 per group) were treated with either PBS, ceftazidime, phage øFG02, or the combination of phage and ceftazidime. The second stage involved only the latter two groups ( n = 5 per group), with a prolonged endpoint of 16 h. The primary outcome was the average bacterial burden from four body sites (blood, liver, kidney, and spleen). Bacterial colonies from phage-treated mice were retrieved and screened for phage-resistance. Findings In the first stage, the bacterial burden (CFU/g of tissue) of the combination group (median: 4.55 × 10 5 ; interquartile range [IQR]: 2.79 × 10 5 –2.81 × 10 6 ) was significantly lower than the PBS (median: 2.42 × 10 9 ; IQR: 1.97 × 10 9 –3.48 × 10 9 ) and ceftazidime groups (median: 3.86 × 10 8 ; IQR: 2.15 × 10 8 –6.35 × 10 8 ), but not the phage-only group (median: 1.28 × 10 7 ; IQR: 4.71 × 10 6 –7.13 × 10 7 ). In the second stage, the combination treatment (median: 1.72 × 10 6 ; IQR: 5.11 × 10 5 –4.00 × 10 6 ) outperformed the phage-only treatment (median: 7.46 × 10 7 ; IQR: 1.43 × 10 7 –1.57 × 10 8 ). Phage-resistance emerged in 96% of animals receiving phages, and all the tested isolates ( n = 11) had loss-of-function mutations in genes involved in capsule biosynthesis and increased sensitivity to ceftazidime. Interpretation øFG02 reliably drives the in vivo evolution of A. baumannii AB900 towards a capsule-deficient, phage-resistant phenotype that is resensitised to ceftazidime. This mechanism highlights the clinical potential of using phage therapy to target A. baumannii and restore antibiotic activity. Funding National Health and Medical Research Council (Australia).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Wiegand, I., Hilpert, K., & Hancock, R. E. W. (2008) · Nature Protocols · doi:10.1038/nprot.2007.521 · Cited by 6,156
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000410 · Cited by 5,939
Cited by
Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities
Venkataraman, S., Shahgolzari, M., Yavari, A., & Hefferon, K. (2025) · Bioengineering · doi:10.3390/bioengineering12050469 · Cited by 38
Metadata
- Authors
- Gordillo Altamirano, F. L., Kostoulias, X., Subedi, D., Korneev, D., Peleg, A. Y., & Barr, J. J.
- Venue
- eBioMedicine
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 80
- Pages
- 104045
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W4229068474
- Cited by
- 158
- References
- 3
- FWCI
- 15.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. https://app.cochat.ai/papers/10.1016/j.ebiom.2022.104045
- The paper
- Gordillo Altamirano, F. L., Kostoulias, X., Subedi, D., Korneev, D., Peleg, A. Y., & Barr, J. J. (2022). Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. eBioMedicine. https://doi.org/10.1016/j.ebiom.2022.104045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.